Lytix Biopharma Feed

Land	Norge
Lista	Euronext Growth Oslo
Sektor	Hälsovård
Industri	Bioteknik

2024-04-12 07:00:00 Lytix Biopharma AS - Ex Date -2,48% | 0,08 MNOK

2024-04-10 23:48:17 Lytix Biopharma AS: Tilbud om tegning av aksjer, publisering av prospekt og innkalling til ekstraordinær generalforsamling -4,41% | 0,19 MNOK

2024-04-10 14:20:57 Lytix Biopharma AS - Notice of extraordinary general meeting 25 April 2024 -1,99% | 0,26 MNOK

2024-04-10 12:47:04 Lytix Biopharma AS - Publication of Prospectus and commencement of Application Period -1,99% | 0,26 MNOK

2024-04-09 18:12:15 Lytix Biopharma AS - Key information relating to the share offer -1,99% | 0,26 MNOK

2024-04-09 17:45:26 Lytix Biopharma raising up to NOK 55 million with strong support from existing shareholders - several key milestones coming up with large commercial potential -1,99% | 0,26 MNOK

2024-04-09 17:10:49 LYTIX BIOPHARMA AS: Contemplated Offering -1,99% | 0,26 MNOK

2024-04-02 12:54:54 LYTIX: Lytix`s approach to raise response rates to immunotherapy highlighted in the international publication MedNous +11,15% | 0,62 MNOK

2024-03-21 12:43:49 LYTIX: Lytix Biopharma announces the publication of a paper describing how LTX-315 mediates antitumor activity through multiple pathways +0,75% | 0,72 MNOK

2024-03-20 14:54:39 LYTIX: Financial calendar +0,75% | 0,08 MNOK

2024-02-29 08:00:00 Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients -9,23% | 0,97 MNOK

2024-02-22 10:36:25 Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2023 results, Thursday 29 February 2024 -8,09% | 0,33 MNOK

2024-01-26 12:42:34 LYTIX: Financial calendar +2,05% | 1,32 MNOK

2024-01-23 10:39:04 LYTIX: Lytix Biopharma presenting at Redeye Fight Cancer Event 2024 -0,77% | 0,20 MNOK

2024-01-05 15:18:44 LYTIX: Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma +61,32% | 2,20 MNOK

2023-12-29 17:58:47 LYTIX: Financial calendar +2,88% | 0,03 MNOK

2023-12-11 13:14:11 LYTIX: Encouraging results from ATLAS-IT-04 study published in OncoImmunology +6,54% | 1,00 MNOK

2023-11-09 08:00:00 LYTIX: Lytix Biopharma presents third quarter 2023 results -5,80% | 0,47 MNOK

2023-11-08 12:00:00 LYTIX: Lytix Biopharma presenting at major investor conferences in London and Stockholm in November +4,55% | 0,33 MNOK

2023-11-02 08:00:00 Lytix Biopharma: Presentation of third quarter 2023 results, November 9 0,00% | 0,54 MNOK

2023-10-25 13:23:26 LYTIX: Financial calendar +1,52% | 0,62 MNOK

2023-10-23 08:00:00 LYTIX: Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023 -4,79% | 0,80 MNOK

2023-10-20 09:00:00 LYTIX: Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05 +3,55% | 1,67 MNOK

2023-10-17 08:00:00 LYTIX: Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from 'SkatteFUNN' -2,14% | 0,51 MNOK

2023-10-16 08:51:55 LYTIX: Lytix Biopharma's abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published -1,41% | 0,21 MNOK

2023-10-09 15:00:00 LYTIX: Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting -1,54% | 1,08 MNOK

2023-08-31 08:00:00 LYTIX: Lytix Biopharma presents first half and second quarter 2023 results -1,56% | 0,19 MNOK

2023-08-28 13:48:13 LYTIX: Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial -4,95% | 2,19 MNOK

2023-08-24 08:00:00 Lytix Biopharma: Presentation of second quarter 2023 results, August 31 -4,17% | 0,30 MNOK

2023-08-11 08:00:00 LYTIX: Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315 +8,59% | 5,11 MNOK

2023-08-03 14:37:17 LYTIX: Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the 2023 American Academy of Dermatology Association's Innovation Academy meeting +7,69% | 0,08 MNOK

2023-07-20 08:00:00 LYTIX: Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023 +1,43% | 0,02 MNOK

2023-06-21 22:49:15 Lytix Biopharma AS: GRANT OF SHARE OPTIONS -8,28% | 0,18 MNOK

2023-05-25 08:00:00 LYTIX: Lytix Biopharma to present at ABG Sundal Collier Life Science Summit and Redeye Growth Day in Stockholm +4,71% | 0,29 MNOK

2023-05-11 08:00:00 LYTIX: Lytix Biopharma presents first quarter 2023 results -8,96% | 0,59 MNOK

2023-05-04 08:00:00 Lytix Biopharma: Presentation of first quarter 2023 results, Thursday 11 May +3,82% | 0,08 MNOK

2023-05-03 07:55:34 LYTIX: Lytix Biopharma to present at the 'Frontiers in Cancer Immunotherapy 2023', invited by New York Academy of Sciences 0,00% | 0,01 MNOK

2023-04-19 08:01:31 LYTIX: Lytix Biopharma appoints new Chairman of the Board +0,76% | 0,04 MNOK

2023-04-18 16:50:19 Lytix Biopharma AS: GRANT OF SHARE OPTIONS +0,76% | 0,04 MNOK

2023-04-18 16:46:10 Lytix Biopharma - Minutes of Ordinary General Meeting +0,76% | 0,04 MNOK

2023-04-11 10:17:32 Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 +10,61% | 0,43 MNOK

2023-03-30 08:00:00 Lytix Biopharma: Annual Report for 2022 +6,77% | 0,02 MNOK

2023-02-16 08:00:00 LYTIX: Lytix Biopharma presents fourth quarter and second half 2022 results +2,62% | 1,02 MNOK

2023-02-09 08:00:00 Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February -7,86% | 0,01 MNOK

2022-12-15 15:08:14 LYTIX: Financial calendar -9,41% | 0,25 MNOK

2022-12-15 15:08:14 LYTIX: Finansiell kalender -9,41% | 0,25 MNOK

2022-12-14 19:15:05 Lytix Biopharma AS: GRANT OF SHARE OPTIONS -9,41% | 0,25 MNOK

2022-11-17 08:00:00 LYTIX: Lytix Biopharma third quarter 2022 results -7,05% | 0,20 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2024-11-14	Kvartalsrapport 2024-Q3
2024-08-29	Kvartalsrapport 2024-Q2
2024-05-30	Kvartalsrapport 2024-Q1
2024-04-25	Extra Bolagsstämma 2024
2024-04-19	Ordinarie utdelning LYTIX 0.00 NOK
2024-04-18	Årsstämma 2024
2024-02-29	Bokslutskommuniké 2023
2023-11-09	Kvartalsrapport 2023-Q3
2023-08-31	Kvartalsrapport 2023-Q2
2023-05-11	Kvartalsrapport 2023-Q1
2023-04-19	Ordinarie utdelning LYTIX 0.00 NOK
2023-04-18	Årsstämma 2023
2023-02-16	Bokslutskommuniké 2022
2022-11-17	Kvartalsrapport 2022-Q3
2022-08-25	Kvartalsrapport 2022-Q2
2022-05-12	Kvartalsrapport 2022-Q1
2022-04-22	Ordinarie utdelning LYTIX 0.00 NOK
2022-04-21	Årsstämma 2022
2022-02-17	Bokslutskommuniké 2021

Lytix Biopharma

Kalender

Beskrivning

Lytix Biopharma

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden